推薦產品
等級
pharmaceutical primary standard
API 家族
cisplatin
製造商／商標名
EDQM
mp
270 °C (lit.)
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
N.N.Cl[Pt]Cl
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChI 密鑰
LXZZYRPGZAFOLE-UHFFFAOYSA-L
尋找類似的產品？ 前往 產品比較指南
一般說明
應用
本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途，用户请自行负责。本标准品不适用于人类或动物使用。
根据欧洲药典，用于配制下列给定溶液：
根据欧洲药典，用于配制下列给定溶液：
- 鉴定参考溶液，根据各论 0559，采用红外吸收光谱法和薄层色谱法检测相关物质，使用采用液相色谱法（通则 2.2.29）检测顺铂
- 参考溶液 (b)，根据各论 1081，使用液相色谱法（通则 2.2.29）检测异麦芽酮糖醇中的相关物质
生化／生理作用
强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物，诱导链内交联。
包裝
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
其他說明
相应销售限制条件可能适用。
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Cisplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2231-2232 (2009)
Michael F Milosevic et al.
International journal of cancer, 135(7), 1692-1699 (2013-08-02)
Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
文章
Antineoplastic agents separated with excellent resolution.
Antineoplastic agents separated with excellent resolution.
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務